Form 4: Recursion Pharmaceuticals Director Dean Y. Li Acquires Shares Through Compensation Policy

Dean Y. Li, a Director at Recursion Pharmaceuticals, Inc. (RXRX), acquired 1,949 shares of Class A Common Stock as part of the company's Outside Director Compensation Policy.

Summary

• Dean Y. Li, a Director of Recursion Pharmaceuticals, Inc. (RXRX), acquired 1,949 shares of Class A Common Stock on July 1, 2025.
• The shares were issued at a price of $0, indicating they were granted as compensation.
• This acquisition was made pursuant to the Issuer's Outside Director Compensation Policy.
• Following this transaction, Dean Y. Li directly beneficially owns 1,236,567 shares of Class A Common Stock.
• Additionally, Dean Y. Li indirectly beneficially owns 1,422,048 shares through the Dean Y. Li Revocable Trust, 136,981 shares through the Dean Y. Li GRAT, and 421,000 shares through the Dean Y. Li 2021 Family Trust.

Sentiment

Score: 7

Explanation: The document reports a routine, expected insider acquisition of shares as part of a compensation policy. This is generally viewed positively as it aligns director interests with shareholders, without indicating any negative or unexpected events.

Positives

• The acquisition of shares by a director aligns their interests with those of shareholders, potentially signaling confidence in the company's future.
• The transaction is part of a structured compensation policy, indicating a standard and expected form of director remuneration.

Future Outlook

The document does not provide forward-looking statements or guidance beyond the reported transaction.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common across all industries for publicly traded companies. It reflects standard compensation practices for board members in the biotechnology or pharmaceutical sector.

Comparison to Industry Standards

• The issuance of shares as part of an 'Outside Director Compensation Policy' is a standard practice for public companies across various industries, including biotechnology and pharmaceuticals, to align director interests with shareholders.
• The disclosure format and content adhere to SEC regulations for insider trading reports (Form 4), consistent with global benchmarks for transparency in financial markets.

Corporate Governance

Stakeholder Impact

• Shareholders: The acquisition of shares by a director, even as compensation, can be viewed positively as it increases their personal stake in the company's performance, potentially signaling confidence and aligning interests.

Key Dates

Keywords

Recursion Pharmaceuticals, RXRX, Dean Y. Li, SEC Form 4, Insider Transaction, Stock Acquisition, Director Compensation, Beneficial Ownership, Class A Common Stock